Tekmira Pharmaceuticals Corp. has entered into a research collaboration with Bristol-Myers Squibb using Tekmira's SNALP technology to deliver small interfering RNAs (siRNAs) to specific organs and tissues outside of the liver.
The two companies previously worked together using siRNA delivery technology provided by Protiva Biotherapeutics. In May, Protiva and Tekmira combined their businesses. The collaboration between BMS and Protiva focused on validating certain gene targets using small interfering RNAs provided by BMS and employed a number of different stable nucleic-acid lipid particle (SNALP) formulations. SNALP is Tekmira's proprietary lipid nanoparticle technology for the delivery of RNAi drugs, including siRNAs.
Dr. Mark J. Murray, Tekmira's president and chief executive officer, said, "Our relationship with Bristol-Myers Squibb is consistent with our strategy to work with global pharmaceutical leaders to expand the therapeutic potential of our leading RNAi delivery technology. At the same time, this work compliments our internal product development initiatives as we advance our own RNAi therapeutics to treat serious human diseases."